Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.…
Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
Scinai Immunotherapeutics (NASDAQ: SCNI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 45 employees.
The shares were at 1.580 USD on 20 November 2026, down 96.4% over 52 weeks. Its 52-week range is 1.146 USD to 52.00 USD: the price is 97.0% below the high and 37.8% above the low.
Its market capitalisation is 1.04M USD.
Scinai Immunotherapeutics reports return on equity of -102.5%, an operating margin of -276.1% and revenue up 572.5% year over year.
Its debt exceeds its cash by 1.68M USD, a debt-to-equity ratio of 0.28. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.